Circulating metastasis associated in colon cancer 1 transcripts in gastric cancer patient plasma as diagnostic and prognostic biomarker
Open Access
- 1 January 2015
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (1), 333-341
- https://doi.org/10.3748/wjg.v21.i1.333
Abstract
AIM: To evaluate the diagnostic and prognostic value of circulating Metastasis Associated in Colon Cancer 1 (MACC1) transcripts in plasma of gastric cancer patients. METHODS: We provide for the first time a blood-based assay for transcript quantification of the metastasis inducer MACC1 in a prospective study of gastric cancer patient plasma. MACC1 is a strong prognostic biomarker for tumor progression and metastasis in a variety of solid cancers. We conducted a study to define the diagnostic and prognostic power of MACC1 transcripts using 76 plasma samples from gastric cancer patients, either newly diagnosed with gastric cancer, newly diagnosed with metachronous metastasis of gastric cancer, as well as follow-up patients. Findings were controlled by using plasma samples from 54 tumor-free volunteers. Plasma was separated, RNA was isolated, and levels of MACC1 as well as S100A4 transcripts were determined by quantitative RT-PCR. RESULTS: Based on the levels of circulating MACC1 transcripts in plasma we significantly discriminated tumor-free volunteers and gastric cancer patients (P < 0.001). Levels of circulating MACC1 transcripts were increased in gastric cancer patients of each disease stage, compared to tumor-free volunteers: patients with tumors without metastasis (P = 0.005), with synchronous metastasis (P = 0.002), with metachronous metastasis (P = 0.005), and patients during follow-up (P = 0.021). Sensitivity was 0.68 (95%CI: 0.45-0.85) and specificity was 0.89 (95%CI: 0.77-0.95), respectively. Importantly, gastric cancer patients with high circulating MACC1 transcript levels in plasma demonstrated significantly shorter survival when compared with patients demonstrating low MACC1 levels (P = 0.0015). Furthermore, gastric cancer patients with high circulating transcript levels of MACC1 as well as of S100A4 in plasma demonstrated significantly shorter survival when compared with patients demonstrating low levels of both biomarkers or with only one biomarker elevated (P = 0.001). CONCLUSION: Levels of circulating MACC1 transcripts in plasma of gastric cancer patients are of diagnostic value and are prognostic for patient survival in a prospective study.Keywords
This publication has 26 references indexed in Scilit:
- Expression of MACC1 and c-Met in human gastric cancer and its clinical significanceCancer Cell International, 2013
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal Of Cancer, 2013
- Overexpression of S100A4 is closely associated with the progression and prognosis of gastric cancer in young patientsOncology Letters, 2013
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Colon cancer metastasis: MACC1 and Met as metastatic pacemakersThe International Journal of Biochemistry & Cell Biology, 2009
- Prognostic importance of epithelial–mesenchymal transition‐related protein expression in gastric carcinomaHistopathology, 2009
- MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasisNature Medicine, 2008
- The Metastasis-Associated Gene S100A4 Is a Novel Target of β-catenin/T-cell Factor Signaling in Colon CancerGastroenterology, 2006
- Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancerThe American Journal of Surgery, 2001
- Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma.Tumor Biology, 2001